Type 2 diabetes patient looking at phone

Savings and support

Eligible patients with commercial insurance can pay as little as $5 per month with the BASAGLAR Savings Card*. For further assistance please see below.

If you would like to keep your Savings Card on your phone or tablet, download the Beginning BASAGLAR app

*Applies to each of your first 24 prescriptions. Boehringer Ingelheim and Lilly pay up to $150/month. This offer is invalid for patients whose prescription claims are eligible to be reimbursed, in whole or in part, by any governmental program. See back of Savings Card for additional details/restrictions.

Already have a BASAGLAR® (insulin glargine injection) 100 units/mL Savings Card?

Click on the button to activate your savings card and start saving with your next prescription.

Lilly Diabetes Solution Center

Lilly Diabetes Solution Center

If you need help paying for your BASAGLAR prescription or diabetes care, call the Lilly Diabetes Solution Center at
1-833-808-1234, Monday through Friday from 9 AM to 8 PM, ET. A representative will have a confidential conversation with you and determine your eligibility for solutions based on your circumstances.

Using a mail order pharmacy?

Eligible patients can still save on BASAGLAR. Just mail in a copy of your activated BASAGLAR Savings Card along with your receipt, name of drug, date filled and amount paid, and your name and address to:

BASAGLAR Savings Program
PO Box 42638
Cincinnati, OH 45242-0638

A check will be mailed directly to you within 1-2 weeks. If you send incorrect documentation, you will receive a letter explaining why your request has been rejected and how to resubmit.

BASAGLAR savings progam mailing address
Phone-based Support Programs

Patient support program

To help you get off to a good start with BASAGLAR, we offer a phone-based support program. Eligible patients can sign up for live phone calls with a trained health mentor who can help you get started on BASAGLAR, explain BASAGLAR in more detail, and answer questions you might have. Find out if you're eligible for the program by calling 1-855-232-1059.

If you have general questions about BASAGLAR, give us a call at 1-800-LillyRx (1-800-545-5979),
Mon-Fri, 9 AM-8 PM ET.

Indications and Important Safety Information

BASAGLAR is a long-acting insulin used to control high blood sugar in adults and children with type 1 diabetes and adults with type 2 diabetes.


BASAGLAR is not for treating diabetic ketoacidosis.


Do not take BASAGLAR during episodes of low blood sugar or if you are allergic to insulin glargine or any of the ingredients in BASAGLAR.

Do NOT reuse needles or share insulin pens, even if the needle has been changed.

Before starting BASAGLAR, tell your doctor about all your medical conditions, including if you have liver or kidney problems, if you are pregnant or planning to become pregnant, or if you are breastfeeding or planning to breastfeed.

BASAGLAR should be taken once a day at the same time every day. Test your blood sugar levels while using insulin. Do not make any changes to your dose or type of insulin without talking to your healthcare provider. Any change of insulin should be made cautiously and only under medical supervision.

The most common side effect of insulin, including BASAGLAR, is low blood sugar (hypoglycemia), which may be serious and life threatening. Signs and symptoms may include dizziness or light-headedness, sweating, confusion, headache, blurred vision, slurred speech, shakiness, fast heartbeat, anxiety, irritability, mood change, or hunger.

Do NOT dilute or mix BASAGLAR with any other insulin or solution. It will not work as intended and you may lose blood sugar control, which could be serious. BASAGLAR must only be used if the solution is clear and colorless with no particles visible. Always make sure you have the correct insulin before each injection.

BASAGLAR may cause serious side effects that can lead to death, such as severe allergic reactions. Get emergency help if you have:

  • A rash over your whole body
  • Trouble breathing
  • A fast heartbeat
  • Sweating
  • Swelling of your face, tongue, or throat
  • Shortness of breath
  • Extreme drowsiness, dizziness, or confusion

Heart failure can occur if you are taking insulin together with medicines called TZDs (thiazolidinediones), even if you have never had heart failure or other heart problems. If you already have heart failure, it may get worse while you take TZDs with BASAGLAR. Your treatment with TZDs and BASAGLAR may need to be changed or stopped by your doctor if you have new or worsening heart failure. Tell your doctor if you have any new or worsening symptoms of heart failure, including:

  • Shortness of breath
  • Swelling of your ankles or feet
  • Sudden weight gain

Tell your doctor about all the medications you take, including over-the-counter medicines, vitamins, and herbal supplements.

While using BASAGLAR, do not drive or operate heavy machinery until you know how BASAGLAR affects you. Do not drink alcohol or use other medicines that contain alcohol.

Other possible side effects may include swelling, weight gain, low potassium, injection site reactions, including changes in fat tissue at the injection site, and allergic reactions. These are not all the possible side effects. Call your doctor for medical advice about side effects.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

The BASAGLAR KwikPen® is a disposable, prefilled insulin pen. Please talk to your healthcare provider about proper injection technique and follow instructions in the Instructions for Use that accompanies the pen. BASAGLAR is available by prescription only.


1. Basaglar [Prescribing Information]. Indianapolis, IN: Eli Lilly & Co. 2. Linnebjerg H, Lam EC, Seger ME, et al. Comparison of the pharmacokinetics and pharmacodynamics of LY2963016 insulin glargine and European Union- and U.S.- approved versions of Lantus insulin glargine in healthy subjects: three randomized euglycemic clamp studies. Diabetes Care. 2015 Aug 15. doi: 10.2337/dc14-2623.